文献速递前列腺癌

特定胶原相关转录组、蛋白质组和尿液组特征预测临床显著性前列腺癌

Prediction of Clinically Significant Prostate Cancer by a Specific Collagen-related Transcriptome, Proteome, and Urinome Signature.
PubMed 文献 · Eur Urol Oncol · 2024-06-08

本研究分析前列腺癌转录组(n=1393)、蛋白质组(n=104)和尿液组(n=923)数据中55个胶原相关基因,发现30个基因和34个蛋白在临床显著性前列腺癌(csPCa,ISUP分级组≥2)中差异表达,建立的胶原机器学习模型优于PSA和年龄,与多参数磁共振(mpMRI)性能相当;基于尿液组的胶原模型在PI-RADS 3病变患者中识别出5例csPCa中的4例。研究为回顾性,尿液组胶原特征作为液体活检工具需前瞻性评估。

要点

  • 胶原相关转录组、蛋白质组和尿液组特征检测csPCa的准确性优于PSA和年龄。
  • 胶原模型预测csPCa的性能与mpMRI相当。
  • 尿液组胶原模型在PI-RADS 3病变患者中识别出5例csPCa中的4例。

核心结论

  • 胶原相关转录组、蛋白质组和尿液组特征检测csPCa的准确性优于PSA和年龄。
  • 胶原特征尤其在mpMRI病变性质不明确时成功识别csPCa,可能减少不必要的活检。
  • 基于尿液组的胶原特征是有前景的液体活检工具,需前瞻性评估以改善前列腺癌诊断精确性、风险分层和指导个性化干预。

研究设计与样本

  • 研究分析前列腺癌转录组(n=1393)、蛋白质组(n=104)和尿液组(n=923)数据集,聚焦55个胶原相关基因。
  • 通过单细胞RNA测序探究胶原相关转录本的细胞来源。
  • 使用统计评估、聚类和机器学习模型识别csPCa特征。
  • 研究为回顾性。

主要发现

  • 与良性前列腺组织或ISUP 1级癌相比,csPCa中确认55个胶原相关基因中的30个基因和34个蛋白质差异表达。
  • 胶原高表达癌聚类表现出独特的细胞和分子特征,包括成纤维细胞和内皮细胞浸润、强烈的细胞外基质更新以及增强的生长因子和炎症信号。
  • 建立了稳健的基于胶原的机器学习模型识别csPCa,模型优于PSA和年龄,预测csPCa性能与mpMRI相当。
  • 基于尿液组的胶原模型在PI-RADS 3病变患者中识别出5例csPCa中的4例。

临床怎么用

  • 作者认为胶原特征尤其在mpMRI病变性质不明确时成功识别csPCa,可能减少不必要的活检。
  • 作者认为基于尿液组的胶原特征是有前景的液体活检工具,需前瞻性评估以改善前列腺癌诊断精确性、风险分层和指导个性化干预。

局限性

  • 研究的回顾性特征是局限性。
  • 基于尿液组的胶原特征需前瞻性评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: While collagen density has been associated with poor outcomes in various cancers, its role in prostate cancer (PCa) remains elusive. Our aim was to analyze collagen-related transcriptomic, proteomic, and urinome alterations in the context of detection of clinically significant PCa (csPCa, International Society of Urological Pathology [ISUP] grade group ≥2). METHODS: Comprehensive analyses for PCa transcriptome (n = 1393), proteome (n = 104), and urinome (n = 923) data sets focused on 55 collagen-related genes. Investigation of the cellular source of collagen-related transcripts via single-cell RNA sequencing was conducted. Statistical evaluations, clustering, and machine learning models were used for data analysis to identify csPCa signatures. KEY FINDINGS AND LIMITATIONS: Differential expression of 30 of 55 collagen-related genes and 34 proteins was confirmed in csPCa in comparison to benign prostate tissue or ISUP 1 cancer. A collagen-high cancer cluster exhibited distinct cellular and molecular characteristics, including fibroblast and endothelial cell infiltration, intense extracellular matrix turnover, and enhanced growth factor and inflammatory signaling. Robust collagen-based machine learning models were established to identify csPCa. The models outcompeted prostate-specific antigen (PSA) and age, showing comparable performance to multiparametric magnetic resonance imaging (mpMRI) in predicting csPCa. Of note, the urinome-based collagen model identified four of five csPCa cases among patients with Prostate Imaging-Reporting and Data System (PI-IRADS) 3 lesions, for which the presence of csPCa is considered equivocal. The retrospective character of the study is a limitation. CONCLUSIONS AND CLINICAL IMPLICATIONS: Collagen-related transcriptome, proteome, and urinome signatures exhibited superior accuracy in detecting csPCa in comparison to PSA and age. The collagen signatures, especially in cases of ambiguous lesions on mpMRI, successfully identified csPCa and could potentially reduce unnecessary biopsies. The urinome-based collagen signature represents a promising liquid biopsy tool that requires prospective evaluation to improve the potential of this collagen-based approach to enhance diagnostic precision in PCa for risk stratification and guiding personalized interventions. PATIENT SUMMARY: In our study, collagen-related alterations in tissue, and urine were able to predict the presence of clinically significant prostate cancer at primary diagnosis.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Heidegger I, Frantzi M, Salcher S, et al. Prediction of Clinically Significant Prostate Cancer by a Specific Collagen-related Transcriptome, Proteome, and Urinome Signature. Eur Urol Oncol. 2024. PMID: 38851995. doi:10.1016/j.euo.2024.05.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。